|
市場調查報告書
核酸檢查：個人化醫療的刺激手段
Nucleic Acid Testing: A Vehicle for Advancing Personalized Medicine
|
核酸檢查：個人化醫療的刺激手段 是由出版商Decision Resources, Inc.在2009年04月所出版的。
這份英文市場調查報告書包含29 Pages 價格從美金3450起跳。
分子診斷中發展最快速的莫過於核酸檢查（NAT）了。NAT擔負生命科學產業的重要角色，有助於改善醫療及促進個人化醫療的發展。
本報告書內容包括：個人化醫療發展中NAT的重要性及NAT領域的企業M&A、合作、授權活動、未來動向等。內容綱要摘記如下：
實施概要
核酸檢查（NAT）介紹
- 促進個人化醫療的發展
- 影響藥物開發及許可
- 領導分子診斷檢查技術
- 報告書的範圍
NAT工具箱：現在及未來的技術
NAT市場的技術動向
- 血液篩檢及傳染病
- 性傳染症檢查
- 院内傳染檢查
- HIV藥物抗藥性檢查
- 傳染性呼吸器官疾病
- 癌症
- 遺傳性風險檢查
- 早期篩選檢查
- 標靶治療檢查
- 癌症預後診斷檢查
- 治療方法誘導檢查
NAT相關企業領導者
未來動向
- 可預見的未來引導NAT市場發展的應用領域
- 主要企業透過收購或授權活動成長
- NAT檢查的價值雖高，但有必要檢驗其成本效益
圖表
Abstract
Introduction
One of the fastest-growing segments of molecular diagnostics is nucleic acid
testing (NAT). NAT is central to the life sciences industry, to improved
healthcare, and to personalized medicine. Tools based on NAT are used to
discover new biomarkers and develop in vitro diagnostics. Companies large and
small are recognizing the value of NAT, and both R&D and dealmaking activity
is robust. Find out who the players are and how they are vying for commercial
success.
Get the Answers You Need to Shape Your Strategy
- NAT is a leading molecular diagnostics technology. What are the advantages
of NAT over other molecular diagnostics technologies? Which elements of NAT
will drive personalized medicine forward?
- Polymerase chain reaction (PCR) is one of the most common methods in the
NAT toolbox used to discover new biomarkers and develop diagnostics tests.
What other methods are commonly used for NAT? Which of these methods have the
most product development activity?
- Roche Diagnostics is the clear leader in molecular diagnostics. How do
Roche' s sales fi gures compare with those of smaller diagnostics players? What
does the competition look like within the smaller segments?
- How are companies using dealmaking to advance their positions?
- Infectious disease and oncology are the two main therapy areas for use of
NAT technologies. What are the growth trends and growth drivers within these
therapy areas? What companies are positioned to tap the opportunities?
Scope
- Importance of NAT for advancing personalized medicine: Use of and
rationale for NAT techniques and products to support the push for personalized
medicine.
- Key mergers and acquisitions (M&As), collaboration, and licensing
activities in NAT: Two tables featuring 92 alliances that occurred from
November 2007 through December 2008.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction to NAT - A Central Technology
- Driving the Evolution to Personalized Medicine
- Affecting Drug Discovery and Approval
- Leading the Molecular Diagnostic Assay Technologies
- Scope of the Report
- The NAT Toolbox: Technologies for Now and the Future
- Therapeutic Focus of the NAT Market
- Blood Screening and Infectious Diseases
- Testing for Sexually Transmitted Infections
- Hospital-Acquired Infections Testing
- HIV Drug Resistance Testing
- Infectious Respiratory Diseases
- Oncology
- Hereditary Risk Assays
- Early Detection Assays
- Targeted Therapy Assays
- Assays for Cancer Prognosis
- Assays Guiding Treatment Options
- Company Leaders in NAT
- Future Trends
- Applications That Will Drive the NAT Market for the Foreseeable Future
- Leading Companies in NAT Will Drive Growth Through Acquisitions and
Licensing
- NAT Assays Are High Value, but Tests Need to Demonstrate
Cost-Effectiveness
Sidebar
- Using Discovery Tools to Shape Future NAT Oncology Assays
Tables
- 1. The Nucleic Acid Testing Toolbox
- 2. Validated Genomic Biomarkers for Select Approved Agents
- 3. Select Nucleic Acid Testing Leaders, by Market Segment
- 4. Select Acquisitions in NAT, November 2007-December 2008
- Appendix A. Select Licensing and Collaboration Activities in NAT, November
2007-December 2008
Figures
- 1. NAT Alliances in 2008, by Therapeutic Area
- 2. Algorithm for the Diagnosis of Chronic Hepatitis C
- 3. Cancer Molecular Targets
|
